Icosavax is a biotechnology company that develops virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on respiratory diseases. It researches the IVX-A12 vaccine, a mixture of two different VLP candidates: IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV).